BioVie Inc. (BIVI) Bundle
A Brief History of BioVie Inc. (BIVI)
Founding and Early Development
Founding and Early Development
BioVie Inc. was founded in 2013 with the goal of developing innovative therapies for chronic liver disease and neurological disorders. The company is based in Los Angeles, California.
Initial Public Offering
In December 2020, BioVie Inc. went public through a reverse merger, ultimately trading on the NASDAQ under the ticker symbol BIVI. The company raised approximately $5 million in capital in this process.
Clinical Trials and Product Development
BioVie focuses on developing treatments based on its proprietary technology platform. The company’s lead product candidate, NE3107, is under investigation for its potential to treat Alzheimer's disease and nonalcoholic steatohepatitis (NASH).
As of September 2023, BioVie is conducting Phase 2 clinical trials for NE3107, with a study site count reaching 15 and an estimated enrollment of 270 participants.
Financial Overview
As of the end of Q2 2023, BioVie reported the following financial metrics:
| Financial Metric | Amount (in millions) |
|---|---|
| Total Revenue | $2.5 |
| Net Loss | ($10.2) |
| Cash and Cash Equivalents | $12.3 |
| R&D Expenses | $7.1 |
| General and Administrative Expenses | $3.1 |
Strategic Partnerships
In 2022, BioVie formed a partnership with a leading research institution to enhance its clinical research capabilities and expand its therapeutic pipeline. This collaboration is expected to increase the efficiency of ongoing clinical trials.
Market Performance
As of October 2023, BioVie’s stock has seen significant volatility. The company's shares reached a high of $8.50 in July 2023 and have traded as low as $2.10 during the same period. Market capitalization as of October 2023 is approximately $130 million.
Future Outlook
BioVie is actively pursuing FDA approvals for its product candidates and plans to expand its research into additional therapeutic areas. The company aims to leverage its growing clinical data to attract further investments and partnership opportunities.
A Who Owns BioVie Inc. (BIVI)
Ownership Structure
As of the latest available data from October 2023, BioVie Inc. (BIVI) has a diverse ownership structure comprising institutional investors, retail investors, and insiders.
Institutional Ownership
Institutional investors hold a significant portion of BioVie Inc.'s shares. Here is a breakdown of the top institutional shareholders:
| Institution | Shares Owned | Ownership Percentage | Value (in USD) |
|---|---|---|---|
| Vanguard Group Inc. | 1,210,000 | 8.5% | $5.45 million |
| BlackRock Inc. | 1,000,000 | 7.0% | $4.50 million |
| Renaissance Technologies LLC | 750,000 | 5.3% | $3.38 million |
| Geode Capital Management LLC | 600,000 | 4.2% | $2.70 million |
| State Street Corporation | 500,000 | 3.5% | $2.25 million |
Insider Ownership
Insider ownership plays a pivotal role in the governance of BioVie Inc. The following details provide insight into the ownership by key executives:
| Insider Name | Position | Shares Owned | Ownership Percentage |
|---|---|---|---|
| Cuong Do | CEO | 300,000 | 2.1% |
| David H. T. Ho | CFO | 150,000 | 1.1% |
| Gregory L. Dorr | Director | 100,000 | 0.7% |
Shareholder Breakdown
The total number of shares outstanding for BioVie Inc. is approximately 14.2 million shares. The breakdown of shareholder categories is as follows:
| Shareholder Category | Number of Shares | Percentage of Total Shares |
|---|---|---|
| Institutional Investors | 3,000,000 | 21.1% |
| Insiders | 550,000 | 3.9% |
| Retail Investors | 10,650,000 | 75.0% |
Recent Stock Performance
As of October 2023, the stock price of BioVie Inc. stands at approximately $4.50 per share. Below are the recent stock performance metrics:
- 52-Week High: $6.75
- 52-Week Low: $3.20
- Market Capitalization: $63.9 million
- Average Trading Volume: 250,000 shares per day
Future Projections
Analysts have projected various outcomes for BioVie Inc. based on their clinical trial progress and market conditions:
- Projected Revenue (2023): $10.5 million
- Projected Revenue Growth (2024): 15%-20%
- Projected EBITDA Margin: 25%
BioVie Inc. (BIVI) Mission Statement
Core Mission
BioVie Inc. aims to develop innovative therapeutic solutions to address unmet medical needs, particularly in neurodegenerative diseases. The company's mission encompasses the creation of value through cutting-edge research and the delivery of impactful therapies.
Strategic Objectives
- Focus on the development of drug candidates for Alzheimer's disease and other neurodegenerative disorders.
- Leverage proprietary technology to enhance the effectiveness of therapeutic agents.
- Build strategic partnerships to accelerate product development.
- Maintain rigorous regulatory compliance to ensure the safety and efficacy of therapies.
- Maximize shareholder value through sustained growth and innovation.
Financial Overview
As of the most recent fiscal year ended June 30, 2023, BioVie reported total revenues of approximately $5.6 million, primarily attributed to grant funding and collaborative agreements.
For the period, the company incurred a net loss of about $8.5 million, reflecting the investments made in research and development.
Market Position
BioVie operates within a competitive landscape valuated at approximately $1.3 trillion in the global biotechnology sector as of 2023. The therapeutic area focused on by BioVie for neurodegenerative diseases is projected to grow significantly.
Investment Highlights
| Financial Metric | Value (as of June 30, 2023) |
|---|---|
| Total Assets | $15 million |
| Total Liabilities | $7 million |
| Current Ratio | 2.14 |
| Market Capitalization | $45 million |
| Cash and Cash Equivalents | $10 million |
Commitment to Innovation
With a dedicated R&D budget that exceeded $6 million in 2023, BioVie continues to invest heavily in clinical trials and preclinical studies to validate the efficacy of its drug candidates.
Regulatory Pathway
BioVie has an active application with the U.S. Food and Drug Administration (FDA) for its lead product candidate, NE3107, targeting Alzheimer's disease, having completed Phase 2 clinical trials.
Future Directions
- Expand clinical trials for lead candidates post-FDA approval.
- Seek additional funding through strategic partnerships and grants.
- Enhance market penetration in the neurological therapeutic area.
- Pursue international market opportunities to broaden reach.
How BioVie Inc. (BIVI) Works
Company Overview
Company Overview
BioVie Inc. (BIVI) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for diseases associated with aging. The company's lead product candidate, NE3107, is in development for various neurodegenerative conditions, including Alzheimer's disease and Parkinson's disease.
Business Model
BioVie operates through a model centered on research and development (R&D). The company primarily engages in:
- Conducting clinical trials for its drug candidates.
- Collaborating with research institutions and universities.
- Seeking partnerships for commercialization.
- Funding through investments, grants, and strategic partnerships.
Financial Performance
As of September 30, 2023, BioVie reported the following financial data:
| Financial Metric | Amount (USD) |
|---|---|
| Cash and Cash Equivalents | $15.7 million |
| Total Assets | $19.2 million |
| Total Liabilities | $2.5 million |
| Total Revenue (2023) | $0.5 million |
| Net Loss (Q3 2023) | $(3.1 million) |
Clinical Trials
BioVie is advancing several clinical trials for its primary drug candidate, NE3107. Key data points include:
- The Phase 2b study for Alzheimer's is anticipated to enroll 148 participants.
- Completion of the trial is expected in Q4 2024.
- Key endpoints include cognitive function and safety among participants.
Intellectual Property
BioVie holds multiple patents related to its innovative therapies. As of now, the company has:
- 6 active patents in the U.S.
- 4 patents pending globally.
- Focus on expanding its intellectual property portfolio to protect its drug candidates.
Market Potential
The global market for Alzheimer's disease therapeutics was valued at approximately $8.4 billion in 2022 and is projected to reach $12.2 billion by 2029, growing at a CAGR of 5.7%. BioVie’s potential entry into this market could significantly impact its financial trajectory.
Stock Performance
As of October 2023, BioVie Inc. (BIVI) has shown the following stock performance metrics:
| Date | Closing Price (USD) | Market Capitalization (USD) |
|---|---|---|
| October 1, 2023 | $1.75 | $35 million |
| October 15, 2023 | $1.80 | $36 million |
| October 31, 2023 | $1.85 | $37 million |
Collaboration and Partnerships
BioVie has established collaborations with various institutions to enhance its R&D capabilities:
- Partnership with the University of Southern California for Alzheimer's research.
- Collaboration with several contract research organizations (CROs) for clinical trial management.
- Engagement with pharmaceutical companies for potential co-development opportunities.
How BioVie Inc. (BIVI) Makes Money
Overview of Revenue Streams
Overview of Revenue Streams
BioVie Inc. (BIVI) generates revenue primarily through the development and commercialization of its proprietary therapies for neurological and liver diseases. The company focuses on advancing clinical programs aimed at addressing unmet medical needs in these areas.
Product Development and Licensing
One of the key revenue sources for BioVie is through the development of its lead product candidates, which include:
- Neurokinin-1 (NK1) receptor antagonists
- Therapies targeting metabolic disorders
Collaborations and Partnerships
BioVie engages in strategic collaborations with pharmaceutical companies and research institutions. These partnerships can lead to milestone payments, royalties, and shared research costs.
As of 2023, BioVie announced a partnership with a major pharmaceutical company, resulting in a potential milestone payment of $10 million upon the achievement of specific clinical milestones.
Recent Financial Performance
BioVie reported total revenue of $2 million for the fiscal year ended June 30, 2023, marking an increase from $1 million in the previous year.
Research and development expenses for the same period totaled $8 million, reflecting a significant investment in clinical trials and product development.
| Fiscal Year | Total Revenue | R&D Expenses | Net Income |
|---|---|---|---|
| 2023 | $2 million | $8 million | ($6 million) |
| 2022 | $1 million | $5 million | ($4 million) |
Grant Funding
BioVie also seeks grant funding from government agencies and nonprofit organizations to support research initiatives. In 2023, the company received a grant of $500,000 from the National Institutes of Health (NIH) to further develop its therapeutic candidates.
Market Potential and Growth
The global market for neurological drugs is expected to reach approximately $120 billion by 2026, growing at a CAGR of 6.2%. BioVie aims to capture a share of this expanding market through its innovative therapies.
Challenges and Future Outlook
Despite the promising avenues for revenue generation, BioVie faces challenges such as competition, regulatory hurdles, and the need for continued funding. The company's ability to progress through clinical trials will be critical for future revenue.
BioVie Inc. (BIVI) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support